Join to View Full Profile
1030 Massachusetts AveCambridge, MA 02138
Phone+1 805-890-4210
Dr. Stehman-Breen is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of WashingtonFellowship, Nephrology, 1993 - 1997
University of WashingtonMaster in Public Health, 1994 - 1996- University of WashingtonResidency, Internal Medicine, 1990 - 1993
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1990
Certifications & Licensure
WA State Medical License 1992 - 2025
Clinical Trials
- A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 (Vesleteplirsen) in Patients With Duchenne Muscular Dystrophy (DMD) Start of enrollment: 2018 Feb 05
- Chemotherapy Induced Peripheral Neuropathy Natural History Study (EPIPHANY) Start of enrollment: 2019 Jul 03
Publications & Presentations
PubMed
- 19 citationsDesign and methods of a postmarketing pharmacoepidemiology study assessing long-term safety of Prolia ® (denosumab) for the treatment of postmenopausal osteoporosis ‡Fei Xue, Haijun Ma, Catherine Stehman-Breen, Christine A. Haller, Leonid Katz
Pharmacoepidemiology and Drug Safety. 2013-10-01 - 246 citationsEffects of denosumab on fracture and bone mineral density by level of kidney functionSophie A. Jamal, Östen Ljunggren, Catherine Stehman-Breen, Steven R. Cummings, Michael R. McClung
Journal of Bone and Mineral Research. 2011-08-01 - 158 citationsChronic Kidney Disease and the Risk of End-Stage Renal Disease versus DeathLorien S. Dalrymple, Ronit Katz, Bryan Kestenbaum, Michael G. Shlipak, Mark J. Sarnak
Journal of General Internal Medicine. 2011-04-01
Press Mentions
Chutes & Ladders—Vertex CMO Kewalramani Steps into Pharma's Exclusive Female CEO ClubJuly 26th, 2019
Dyne Therapeutics Appoints Catherine Stehman-Breen to Its Board of DirectorsJune 28th, 2019
Sarepta Therapeutics Announces Appointment of Catherine Stehman-Breen, M.D., M.S. As Chief Medical OfficerApril 3rd, 2017
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
